Neoantigen cancer vaccines:a new star on the horizon  

作　　者：Xiaoling Li Jian You Liping Hong Weijiang Liu Peng Guo Xishan Hao 

机构地区：[1]Cell Biotechnology Laboratory,Tianjin Cancer Hospital Airport Hospital,Tianjin 300308,China [2]National Clinical Research Center for Cancer,Tianjin 300060,China [3]Haihe Laboratory of Synthetic Biology,Tianjin 300090,China [4]Department of Thoracic Oncology,Tianjin Cancer Hospital Airport Hospital,Tianjin 300308,China [5]Department of Thoracic Oncology Surgery,Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China [6]Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China

出　　处：《Cancer Biology & Medicine》2024年第4期274-311,共38页癌症生物学与医学（英文版）

基　　金：supported by grants from the National Clinical Research Center Cancer Fund;the Haihe Laboratory of Synthetic Biology(22HHSWSS00004)。

摘　　要：Immunotherapy represents a promising strategy for cancer treatment that utilizes immune cells or drugs to activate the patient's own immune system and eliminate cancer cells.One of the most exciting advances within this field is the targeting of neoantigens,which are peptides derived from non-synonymous somatic mutations that are found exclusively within cancer cells and absent in normal cells.Although neoantigen-based therapeutic vaccines have not received approval for standard cancer treatment,early clinical trials have yielded encouraging outcomes as standalone monotherapy or when combined with checkpoint inhibitors.Progress made in high-throughput sequencing and bioinformatics have greatly facilitated the precise and efficient identification of neoantigens.Consequently,personalized neoantigen-based vaccines tailored to each patient have been developed that are capable of eliciting a robust and long-lasting immune response which effectively eliminates tumors and prevents recurrences.This review provides a concise overview consolidating the latest clinical advances in neoantigen-based therapeutic vaccines,and also discusses challenges and future perspectives for this innovative approach,particularly emphasizing the potential of neoantigen-based therapeutic vaccines to enhance clinical efficacy against advanced solid tumors.

关 键 词：IMMUNOTHERAPY neoantigen cancer vaccine solid tumors high-throughput sequencing BIOINFORMATICS PDOs AI HLA TCR 

分 类 号：R392[医药卫生—免疫学]